drugset / Trial / NCT01068626

Rosuvastatin in Visceral Adiposity

NCT01068626

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate whether 6 months treatment with the cholesterol-lowering drug rosuvastatin may reduce visceral fat tissue in obese middle aged men.

Timeline

Start
2006-05
Primary completion
2008-10
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rosuvastatin Small molecule 10 mg